Results 61 to 70 of about 2,817 (204)

Safety of Immune Checkpoint Inhibitors in Cancer Patients With Preexisting Autoimmune Vasculitis

open access: yesACR Open Rheumatology, Volume 8, Issue 3, March 2026.
Objective Immune checkpoint inhibitors (ICIs) are effective cancer therapies but often cause serious immune‐related adverse events (irAEs). Patients with preexisting autoimmune diseases, including vasculitis, are excluded from trials. We aimed to evaluate the frequency, severity, and outcomes of vasculitis flares and irAEs in this population.
Juan Sevillano   +4 more
wiley   +1 more source

Cryoglobulinemic vasculitis in chronic hepatitis C: Genetic aspects [PDF]

open access: yesТерапевтический архив, 2017
Cryoglobulinemia (CG) is detected in more than 50% of patients with chronic hepatitis C (CHC); however, only 15—25% of them develop cryoglobulinemic vasculitis (CV) that is a systemic vasculitis due to the formation of immune deposits, which affects ...
M G Artemova, D T Abdurakhmanov
doaj   +1 more source

Cryoglobulinemic Vasculitis

open access: yes, 2018
Cryoglobulinemia is defined by the presence of circulating immunoglobulins that precipitate at cold temperature and dissolve with rewarming. Cry-oglobulinemia is categorized by immunochemical analysis into three types [1]. Type I cryoglobulins are monoclonal immunoglobulins.
Desbois, Anne C.   +3 more
openaire   +1 more source

HCV and cryoglobulinemic vasculitis.

open access: yesCleveland Clinic Journal of Medicine, 2002
munoglobulinemia)or more immunoglobulins (mixedcryoglobulinemia), which precipitate at temperaturesbelow 37 °C and redissolve on re-warming is termed“cryoglobulinemia.” This is an in vitro phenomenon; theactual mechanism(s) of cryoprecipitation remains obscure.It could be secondary to intrinsic characteristics ofboth mono- and polyclonal immunoglobulin
FERRI, Clodoveo   +9 more
openaire   +5 more sources

The Complement System in ANCA‐Associated Vasculitis: Mechanistic Insights, Therapeutic Horizons, and Unmet Clinical Needs

open access: yesImmunity, Inflammation and Disease, Volume 14, Issue 2, February 2026.
Complement activation, particularly via the alternative pathway, drives inflammation and organ damage in ANCA‐associated vasculitis. This review highlights mechanistic insights, tissue and biomarker evidence, and clinical implications of targeting the C5a–C5aR1 axis.
Kehinde Sunmboye, Pauline Millan
wiley   +1 more source

Cryoglobulinemia: An update on classification, pathophysiology, clinical presentation, and management

open access: yesJournal of Internal Medicine, Volume 299, Issue 2, Page 196-215, February 2026.
Abstract Cryoglobulinemia (CG) is defined by the presence of serum immunoglobulins that precipitate below 37°C and redissolve upon rewarming. It is classified into three types based on immunoglobulin composition. Type I, a rare form, involves monoclonal IgM or IgG and is linked to lymphoproliferative disorders.
Anna Linda Zignego   +7 more
wiley   +1 more source

Recent Progress in Double Filtration Plasmapheresis

open access: yesHemodialysis International, Volume 30, Issue 1, Page 18-25, January 2026.
ABSTRACT Double‐filtration plasmapheresis is an advanced extracorporeal blood purification technique that selectively removes pathogenic macromolecules based on molecular weight. Unlike conventional plasma exchange, double‐filtration plasmapheresis uses a two‐step filtration process to retain beneficial plasma components such as albumin, while ...
Dan Li   +3 more
wiley   +1 more source

Cryoglobulinemic Glomerulonephritis Presenting as Acute Kidney Injury on Chronic Kidney Disease in Rheumatoid Arthritis

open access: yesAnnals of Internal Medicine: Clinical Cases, 2022
Cryoglobulinemic vasculitis (CV) is one of the manifestations of rheumatoid arthritis (RA). Here, we present a case of a 69-year-old woman with uncontrolled long-standing RA who presented with heart failure exacerbation and had an incidental finding of ...
Brinda Basida   +3 more
doaj   +1 more source

Evaluation of the short-term efficacy and safety of biological agents in different rheumatic diseases: a multidisciplinary therapeutic hospital"s experience

open access: yesНаучно-практическая ревматология, 2013
There has been a substantial expansion in the possibilities of current therapy for rheumatic diseases (RD) primarily due to the use of genetically engineered biological agents (GEBA).
N A Mukhin   +20 more
doaj   +1 more source

Home - About - Disclaimer - Privacy